The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. -- There has been no safety concern with the use ...
The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results